Two experimental COVID-19 vaccines ready for clinical trails

• Vaccines are being developed by a Beijing-based unit of Nasdaq-listed Sinovac Biotech, and by the Wuhan Institute of Biological Products.

China has approved two experimental vaccines for early-stage human tests to combat COVID-19 that killed over 100,000 people worldwide.

As per Xinhua, vaccines are being developed by a Beijing-based unit of Nasdaq-listed Sinovac Biotech, and by the Wuhan Institute of Biological Products, an affiliate of state-owned China National Pharmaceutical Group.

In March, China have given go ahead for another clinical trial for a coronavirus vaccine candidate developed by military-backed China's Academy of Military Medical Sciences and HK-listed biotech firm CanSino Bio.

The move came after US drug developer Moderna said it had begun human tests for their vaccine with the U.S. National Institutes of Health.

The World Health Organization (WHO) said Monday that a safe and effective vaccine would be needed to fully halt the spread of Covid-19, which has killed more than 114,000 people worldwide.

"Our global connectedness means the risk of re-introduction and resurgence of Covid-19 will continue," WHO Director-General Tedros Adhanom Ghebreyesus told a virtual briefing from Geneva, stressing that "ultimately, the development and delivery of a safe and effective vaccine will be needed to fully interrupt transmission."